{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:22:06Z","timestamp":1791930126181,"version":"4.3.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.clml.2011.03.018","type":"journal-article","created":{"date-parts":[[2011,6,23]],"date-time":"2011-06-23T02:33:56Z","timestamp":1308796436000},"page":"289-292","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Regression of Hodgkin Lymphoma After Discontinuation of a Tumor Necrosis Factor Inhibitor for Crohn's Disease: A Case Report and Review of the Literature"],"prefix":"10.1016","volume":"11","author":[{"given":"Ryan D.","family":"Cassaday","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey T.","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie E.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2011.03.018_bib1","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1053\/j.gastro.2006.01.047","article-title":"American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease","volume":"130","author":"Lichtenstein","year":"2006","journal-title":"Gastroenterology"},{"issue":"suppl 3","key":"10.1016\/j.clml.2011.03.018_bib2","doi-asserted-by":"crossref","first-page":"iii2","DOI":"10.1136\/ard.2008.100834","article-title":"Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008","volume":"67","author":"Furst","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clml.2011.03.018_bib3","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood-2009-03-212290","article-title":"Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network","volume":"114","author":"Alousi","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.018_bib4","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1164\/rccm.200809-1512OC","article-title":"A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma","volume":"179","author":"Wenzel","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.clml.2011.03.018_bib5","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.clml.2011.03.018_bib6","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.1995.13.5.1080","article-title":"Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report","volume":"13","author":"Bartlett","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.018_bib7","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1136\/ard.2004.033241","article-title":"Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists","volume":"64","author":"Askling","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clml.2011.03.018_bib8","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1002\/art.10679","article-title":"Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration","volume":"46","author":"Brown","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clml.2011.03.018_bib9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00296-007-0391-9","article-title":"Hodgkin's lymphoma following treatment with etanercept in ankylosing spondylitis","volume":"28","author":"Aksu","year":"2007","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.clml.2011.03.018_bib10","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1080\/00365520500529629","article-title":"Rectal Epstein-Barr virus-positive Hodgkin's lymphoma in a patient with Crohn's disease: case report and review of the literature","volume":"41","author":"Bai","year":"2006","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.clml.2011.03.018_bib11","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S0016-5085(99)70294-5","article-title":"The relationship between infliximab treatment and lymphoma in Crohn's disease","volume":"117","author":"Bickston","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clml.2011.03.018_bib12","first-page":"1681","article-title":"Hodgkin's lymphoma associated with anti-TNF use in juvenile idiopathic arthritis: supplemental case report","volume":"35","author":"Imundo","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clml.2011.03.018_bib13","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1182\/blood-2009-07-143545","article-title":"How I treat EBV lymphoproliferation","volume":"114","author":"Heslop","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.018_bib14","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1097\/00007890-200104270-00012","article-title":"Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients","volume":"71","author":"Tsai","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.clml.2011.03.018_bib15","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1097\/00007890-199911270-00015","article-title":"Epstein-Barr virus-induced posttransplant lymphoproliferative disorders","volume":"68","author":"Paya","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.clml.2011.03.018_bib16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/TP.0b013e3181761659","article-title":"Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder","volume":"86","author":"Swinnen","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.clml.2011.03.018_bib17","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1136\/mp.53.5.262","article-title":"Hodgkin's disease and the Epstein-Barr virus","volume":"53","author":"Flavell","year":"2000","journal-title":"Mol Pathol"},{"key":"10.1016\/j.clml.2011.03.018_bib18","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1200\/JCO.2008.16.8252","article-title":"AIDS-related malignancies: state of the art and therapeutic challenges","volume":"26","author":"Spano","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2011.03.018_bib19","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0140-6736(91)92513-2","article-title":"AIDS-associated non-Hodgkin lymphoma","volume":"337","author":"Beral","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2011.03.018_bib20","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1182\/blood.V98.12.3406","article-title":"Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy","volume":"98","author":"Kirk","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.018_bib21","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1182\/blood-2006-05-024109","article-title":"Hodgkin lymphoma and immunodeficiency in persons with HIV\/AIDS","volume":"108","author":"Biggar","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2011.03.018_bib22","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/10428190400015733","article-title":"Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART)","volume":"46","author":"Wolf","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2011.03.018_bib23","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3109\/10428190109057959","article-title":"Changing incidence and survival in patients with AIDS-related non-Hodgkin's lymphomas in the era of highly active antiretroviral therapy (HAART)","volume":"41","author":"Chow","year":"2001","journal-title":"Leuk Lymphoma"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501100019X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501100019X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:21:11Z","timestamp":1761870071000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226501100019X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S215226501100019X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2011.03.018","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regression of Hodgkin Lymphoma After Discontinuation of a Tumor Necrosis Factor Inhibitor for Crohn's Disease: A Case Report and Review of the Literature","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2011.03.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}